CA2321191A1 - Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht3 - Google Patents

Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht3 Download PDF

Info

Publication number
CA2321191A1
CA2321191A1 CA002321191A CA2321191A CA2321191A1 CA 2321191 A1 CA2321191 A1 CA 2321191A1 CA 002321191 A CA002321191 A CA 002321191A CA 2321191 A CA2321191 A CA 2321191A CA 2321191 A1 CA2321191 A1 CA 2321191A1
Authority
CA
Canada
Prior art keywords
ligand
substituted
linker
ligands
linkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002321191A
Other languages
English (en)
Inventor
Guang Yang
Susan Meier-Davis
John H. Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2321191A1 publication Critical patent/CA2321191A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés ou agents à plusieurs liaisons et qui se lient aux récepteurs 5-HT¿3?. Ces composés comportent une pluralité de ligands dont chacun peut se lier à de tels récepteurs, modulant ainsi les fonctions ou processus biologiques de ces récepteurs. Chacun des ligands est attaché par covalence à un lieur ou à des lieurs qui peuvent être identiques ou différents, et ce, de façon à constituer un composé capable de liaisons multiples. Le choix du lieur est fait pour que le composé à liaisons multiples fasse preuve d'une modulation accrue des processus biologiques à médiation du récepteur 5-HT¿3?.
CA002321191A 1998-06-08 1999-06-08 Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht3 Abandoned CA2321191A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8846698P 1998-06-08 1998-06-08
US60/088,466 1998-06-08
US9293898P 1998-07-15 1998-07-15
US60/092,938 1998-07-15
US12028299P 1999-02-16 1999-02-16
US60/120,282 1999-02-16
PCT/US1999/012768 WO1999064046A1 (fr) 1998-06-08 1999-06-08 Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht¿3?

Publications (1)

Publication Number Publication Date
CA2321191A1 true CA2321191A1 (fr) 1999-12-16

Family

ID=27375973

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002321191A Abandoned CA2321191A1 (fr) 1998-06-08 1999-06-08 Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht3

Country Status (4)

Country Link
EP (1) EP1085888A1 (fr)
AU (1) AU4551499A (fr)
CA (1) CA2321191A1 (fr)
WO (1) WO1999064046A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100091A1 (fr) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Moyens et methodes de traitement ameliores utilisant des 'setrones'
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
AU2332497A (en) * 1996-03-19 1997-10-10 Salk Institute For Biological Studies, The (in vitro) methods for identifying modulators of members of the steroid/thyroid superfamily of receptors

Also Published As

Publication number Publication date
WO1999064046A8 (fr) 2001-08-16
WO1999064046A1 (fr) 1999-12-16
AU4551499A (en) 1999-12-30
WO1999064046A9 (fr) 2000-04-20
EP1085888A1 (fr) 2001-03-28

Similar Documents

Publication Publication Date Title
US6355805B1 (en) β3-adrenergic receptor agonists
US6693202B1 (en) Muscarinic receptor antagonists
CA2319495A1 (fr) Inhibiteurs multiliaison de proteine triglyceride transferase microsomique
WO1999064043A9 (fr) Antagonistes des recepteurs muscariniques
US6420560B1 (en) H1—histamine receptor antagonists
WO1999064039A9 (fr) Antagonistes de bradykinine
CA2321191A1 (fr) Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht3
ZA200004083B (en) H1-histamine receptor antagonists.

Legal Events

Date Code Title Description
FZDE Discontinued